Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677507 · ClinicalTrials.gov registry record · Phase 4
Glaucoma Biomarkers
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 135
- Enrollment target
NCT01677507 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 135 participants.
The verdict
NCT01677507, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 135 participants
- Enrollment target
Study Summary
Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments. Current trial-and error approaches to glaucoma management are inefficient and have not addressed this barrier as there are no predictive factors for drug response. Our long-term goal is to improve outcomes by identifying biomarkers and environmental factors that profile a patient at risk for glaucoma by age-of-onset, rate of disease progression, "poor response" to treatment, and large IOP fluctuation. Our purpose of this research project is to address this critical barrier by focusing on physiological factors that predict IOP response to drugs.
Interventions
- DRUG Variation in eye pressure response to timolol and latanoprost treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677507
The ClinicalTrials.gov registry entry for NCT01677507 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Variation in eye pressure response to timolol and latanoprost treatment is the first listed.
NCT01677507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677507 about?
NCT01677507 is a clinical study titled "Glaucoma Biomarkers". Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments. Current trial-and error approaches to glaucoma management are inefficient and have not addre...
What is the current status of trial NCT01677507?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 135 participants. The study started on 2012-08. Estimated completion is 2016-08-30.
What interventions are being tested in trial NCT01677507?
The interventions under investigation include: Variation in eye pressure response to timolol and latanoprost treatment (DRUG).
Who is sponsoring clinical trial NCT01677507?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.